首页> 外文期刊>Molecular and Cellular Biochemistry: An International Journal for Chemical Biology >Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms
【24h】

Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms

机译:呈现多重耐药机制的多重耐药性慢性髓性白血病细胞系的表征

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The multidrug-resistant (MDR) phenotype is multifactorial, and cell lines presenting multiple resistance mechanisms might be good models to understand the importance of the various pathways involved. The present work characterized a MDR chronic myeloid leukemia cell line, derived from K562 through a selective process using daunorubicin. This MDR cell line was shown to be resistant to vincristine, daunorubicin, and partially resistant to imatinib. It showed a slower duplication rate. Overexpression of ABCB1 and ABCC1 was observed at the protein and functional levels and the expression of CD95, a molecule related to cell death, was reduced in the MDR cell line. Conversely, no differences were observed related to the anti-apoptotic molecule Bcl-2 or p53 expression. The activation antigen CD69 was reduced in the MDR cell line and treatment with imatinib further decreased the expressed levels. Furthermore, secretion of IL-8 was diminished in the MDR cell line. When daunorubicin-selected cells were compared to another MDR cell line, Lucena 1, derived from the same parental line K562, and selected with vincristine, a different profile was observed in relation to most aspects studied. When both cell lines were silenced for ABCB1, differences in CD69 and CD95 were maintained, despite resistance reversal. These results reinforce the idea that cell lines selected in vitro may display multiple resistance strategies that may vary with the selective agent used as well as during different steps of the selection process.
机译:多药耐药(MDR)表型是多因素的,呈现多重耐药机制的细胞系可能是了解各种途径重要性的良好模型。本工作的特征是一种通过使用柔红霉素的选择性过程从K562衍生的MDR慢性髓样白血病细胞系。该MDR细胞系显示出对长春新碱,柔红霉素具有抗性,并且对伊马替尼具有部分抗性。它显示出较慢的复制速度。在蛋白质和功能水平上观察到ABCB1和ABCC1的过表达,MDR细胞系中与细胞死亡有关的分子CD95的表达降低。相反,未观察到与抗凋亡分子Bcl-2或p53表达有关的差异。 MDR细胞系中的活化抗原CD69减少,伊马替尼治疗进一步降低了表达水平。此外,在MDR细胞系中IL-8的分泌减少了。当将柔红霉素选择的细胞与另一个MDR细胞系Lucena 1进行比较时,Lucena 1来源于同一亲本系K562,并用长春新碱进行选择,相对于大多数研究方面,观察到了不同的概况。当两个细胞系都沉默ABCB1时,尽管耐药性逆转,但CD69和CD95的差异得以维持。这些结果加强了这样的观念,即体外选择的细胞系可能显示出多种抗性策略,这些策略可能随所用的选择剂以及选择过程的不同步骤而变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号